The FDA Division of Transplant and Ophthalmology Products (DTOP) is hosting a two-day public workshop at the White Oak Campus in Silver Spring, MD entitled, Evidence-Based Treatment Decisions in Transplantation – The Right Dose for the Right Patient: Individualized Treatment. This collaborative workshop will be hosted in partnership with the Transplant Therapeutics Consortium and registration information will be announced ahead of the meeting through the Federal Register.
The Transplant Therapeutics Consortium (TTC) is a joint initiative co-founded by the two leading organizations in organ transplantation: the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS). The TTC is one of numerous public-private partnerships of the Critical Path Institute (C-Path). C-Path is a nonproﬁt organization dedicated to accelerating drug development by fulﬁlling the objectives outlined in the US FDA's Critical Path Initiative. The TTC is convening diverse stakeholders (industry, academia, and government agencies) to support collaborative development and regulatory endorsement of new drug development tools for transplantation which, in turn, may help to shorten the time needed to develop and deliver safe, eﬀective therapies for transplantation patients.
To receive updates about this event as information becomes available, please email us at ASTS@asts.org.